Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma

European Journal of Endocrinology

Volumn 170, Issue 1, 2014, Pages 23-30

  Jeon, Min Ji ^a   Kim, Won Gu ^a   Park, Woo Ri ^a   Han, Ji Min ^a   Kim, Tae Yong ^a   Song, Dong Eun ^a   Chung, Ki Wook ^a   Ryu, Jin Sook ^a   Hong, Suck Joon ^a   Shong, Young Kee ^a   Kim, Won Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN ANTIBODY;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; THYROIDECTOMY; TUMOR ABLATION;

ADULT; AUTOANTIBODIES; CARCINOMA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIVIDUALIZED MEDICINE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84890526126     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0524     Document Type: Article

References (28)

1. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
2. DeGroot LJ, Kaplan EL, McCormick M & Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 71 414-424. (doi:10.1210/jcem-71-2-414)
3. Cady B & Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988 104 947-953.
4. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK & O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997 79 2414-2423. (doi:10.1002/(SICI) 1097-0142(19970615)79:12〈2414::AID-CNCR18〉3.0.CO;2-U)
5. Lang BH, Lo CY, Chan WF, Lam KY & Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Annals of Surgery 2007 245 366-378. (doi:10.1097/01.sla.0000250445.92336.2a)
6. Greene FL, Page DL, Fleming ID, Balch CM & Fritz AG. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual. Springer Verlag, 2002.
7. Davies L & Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 2006 295 2164-2167. (doi:10.1001/jama.295.18.2164)
8. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J & Tatalovich Z. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011.
9. Yang L, Shen W & Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. Journal of Clinical Oncology 2013 31 468-474. (doi:10.1200/JCO.2012.42.4457)
10. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA & Smit JW. Survival and death causes in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 313-319. (doi:10.1210/jc.2005- 1322)
11. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, GonenM, Brokhin M, Omry G, Fagin JA & Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010 20 1341-1349. (doi:10.1089/thy.2010.0178)
12. Vaisman F, Tala H, Grewal R & Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011 21 1317-1322. (doi:10.1089/thy.2011.0232)
13. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M & Tuttle RM. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clinical Endocrinology 2012 77 132-138. (doi:10.1111/j.1365-2265.2012.04342.x)
14. Spencer CA. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). Journal of Clinical Endocrinology and Metabolism 2011 96 3615-3627. (doi:10.1210/jc.2011-1740)
15. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G & Pacini F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. European Journal of Endocrinology 2011 165 441-446. (doi:10.1530/EJE-11-0466)
16. Yim JH, Kim WB, Kim EY, Kim WG, Kim TY, Ryu JS, Gong G, Hong SJ & Shong YK. The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. Journal of Clinical Endocrinology and Metabolism 2011 96 2049-2056. (doi:10.1210/jc.2010-2298)
17. Schemper M. The relative importance of prognostic factors in studies of survival. Statistics in Medicine 1993 12 2377-2382. (doi:10.1002/sim.4780122413)
18. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP & Tuttle RM. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012 22 1144-1152. (doi:10.1089/thy.2012.0043)
19. Han JM, Kim WB, Yim JH, Kim WG, Kim TY, Ryu JS, Gong G, Sung TY, Yoon JH, Hong SJ et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 2012 22 784-790. (doi:10.1089/thy.2011.0322)
20. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 1433-1441. (doi:10.1210/jc.2002-021702)
21. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. Journal of Clinical Endocrinology and Metabolism 2004 89 3702-3704. (doi:10.1210/jc.2004-0986)
22. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ & Shong YK. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2008 93 4683-4689. (doi:10.1210/jc.2008-0962)
23. Gorges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A & Janssen OE. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. European Journal of Endocrinology 2005 153 49-55. (doi:10.1530/eje.1.01940)
24. Gallicchio R, Giacomobono S, Capacchione D, Nardelli A, Barbato F, Nappi A, Pellegrino T & Storto G. Should patients with remnants from thyroidmicrocarcinoma really not be treated with iodine-131 ablation? Endocrine 2013 44 426-433. (doi:10.1007/s12020-013-9935-9)
25. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ & Goellner JR. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008 144 980-987 (discussion 987-988). (doi:10.1016/j.surg.2008.08.035)
26. Mihailovic J, Stefanovic L & Stankovic R. Influence of initial treatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma. Clinical Nuclear Medicine 2013 38 332-338. (doi:10.1097/RLU. 0b013e3182872ed2)
27. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? Journal of Clinical Endocrinology and Metabolism 2012 97 2748-2753. (doi:10.1210/jc.2012-1123)
28. Cho BY, Choi HS, Park YJ, Lim JA, Ahn HY, Lee EK, Kim KW, Yi KH, Chung JK, Youn YK et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013 23 797-804. (doi:10.1089/thy.2012.0329)